NICE Rules Out Sanofi’s Jevtana On Grounds Of Cost Effectiveness
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has turned down Sanofi’s Jevtana for prostate cancer, raising fears in England of a new post-code lottery for cancer drugs and highlighting the different between Germany and England’s health technology assessments.
You may also be interested in...
European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come
It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses
NICE Rejects Jevtana Because Of Cost, But Clears ALK Abello's Bee Sting Prophylaxis
The U.K.'s cost regulator, NICE, rejects Sanofi's lauded prostate cancer therapy cabazitaxel because it considers it too expensive.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.